Exposure to aristolochic acid (AA) is associated with human nephropathy and urothelial cancer. The tumour suppressor TP53 is a critical gene in carcinogenesis and frequently mutated in AA-induced urothelial tumours. We investigated the impact of p53 on AAI-induced nephrotoxicity and DNA damage in vivo by treating Trp53(+/+), Trp53(+/-) and Trp53(-/-) mice with 3.5 mg/kg body weight (bw) AAI daily for 2 or 6 days. Renal histopathology showed a gradient of intensity in proximal tubular injury from Trp53(+/+) to Trp53(-/-) mice, especially after 6 days. The observed renal injury was supported by nuclear magnetic resonance (NMR)-based metabonomic measurements, where a consistent Trp53 genotype-dependent trend was observed for urinary metabolites that indicate aminoaciduria (i.e. alanine), lactic aciduria (i.e. lactate) and glycosuria (i.e. glucose). However, Trp53 genotype had no impact on AAI-DNA adduct levels, as measured by 32P-postlabelling, in either target (kidney and bladder) or non-target (liver) tissues, indicating that the underlying mechanisms of p53-related AAI-induced nephrotoxicity cannot be explained by differences in AAI genotoxicity. Performing gas chromatography-mass spectrometry (GC-MS) on kidney tissues showed metabolic pathways affected by AAI treatment, but again Trp53 status did not clearly impact on such metabolic profiles. We also cultured primary mouse embryonic fibroblasts (MEFs) derived from Trp53(+/+), Trp53(+/-) and Trp53(-/-) mice and exposed them to AAI in vitro (50 µM for up to 48 h). We found that Trp53 genotype impacted on the expression of NAD(P)H:quinone oxidoreductase (Nqo1), a key enzyme involved in AAI bioactivation. Nqo1 induction was highest in Trp53(+/+) MEFs and lowest in Trp53(-/-) MEFs; and it correlated with AAI-DNA adduct formation, with lowest adduct levels being observed in AAI-exposed Trp53(-/-) MEFs. Overall, our results clearly demonstrate that p53 status impacts on AAI-induced renal injury, but the underlying mechanism(s) involved remain to be further explored. Despite the impact of p53 on AAI bioactivation and DNA damage in vitro, such effects were not observed in vivo.

Department of Analytical Environmental and Forensic Sciences MRC PHE Centre for Environment and Health King's College London London SE1 9NH UK

Department of Biochemistry Faculty of Science Charles University Prague 128 40 Prague Czech Republic

Department of Pathology Erasme University Hospital 1070 Brussels Belgium

Department of Surgery and Cancer Faculty of Medicine Imperial College London London W12 0NN UK

Laboratory of Experimental Nephrology Department of Experimental Biochemistry Faculty of Medicine Université Libre de Bruxelles 1070 Brussels Belgium

Zobrazit více v PubMed

Arlt VM, Ferluga D, Stiborova M, et al. Is aristolochic acid a risk factor for Balkan endemic nephropathy-associated urothelial cancer? Int J Cancer. 2002;101(5):500–502. doi: 10.1002/ijc.10602. PubMed DOI

Arlt VM, Stiborova M, Schmeiser HH. Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. Mutagenesis. 2002;17(4):265–277. doi: 10.1093/mutage/17.4.265. PubMed DOI

Arlt VM, Stiborova M, Henderson CJ, et al. Metabolic activation of benzo[a]pyrene in vitro by hepatic cytochrome P450 contrasts with detoxification in vivo: experiments with hepatic cytochrome P450 reductase null mice. Carcinogenesis. 2008;29(3):656–665. doi: 10.1093/carcin/bgn002. PubMed DOI

Arlt VM, Levova K, Barta F, et al. Role of P450 1A1 and P450 1A2 in bioactivation versus detoxication of the renal carcinogen aristolochic acid I: studies in Cyp1a1−/−, Cyp1a2−/−, and Cyp1a1/1a2−/− mice. Chem Res Toxicol. 2011;24(10):1710–1719. doi: 10.1021/tx200259y. PubMed DOI

Arlt VM, Zuo J, Trenz K, et al. Gene expression changes induced by the human carcinogen aristolochic acid I in renal and hepatic tissue of mice. Int J Cancer. 2011;128(1):21–32. doi: 10.1002/ijc.25324. PubMed DOI

Arlt VM, Meinl W, Florian S, et al. Impact of genetic modulation of SULT1A enzymes on DNA adduct formation by aristolochic acids and 3-nitrobenzanthrone. Arch Toxicol. 2017;91(4):1957–1975. doi: 10.1007/s00204-016-1808-6. PubMed DOI PMC

Badawy AA. Kynurenine pathway of tryptophan metabolism: regulatory and functional aspects. Int J Tryptophan Res. 2017;10:1–20. doi: 10.1177/1178646917691938. PubMed DOI PMC

Bakhiya N, Arlt VM, Bahn A, Burckhardt G, Phillips DH, Glatt H. Molecular evidence for an involvement of organic anion transporters (OATs) in aristolochic acid nephropathy. Toxicology. 2009;264:74–79. doi: 10.1016/j.tox.2009.07.014. PubMed DOI

Barta F, Levova K, Frei E, Schmeiser HH, Arlt VM, Stiborova M. The effect of aristolochic acid I on expression of NAD(P)H:quinone oxidoreductase in mice and rats—a comparative study. Mutat Res. 2014;768:1–7. doi: 10.1016/j.mrgentox.2014.01.012. PubMed DOI

Baudoux TE, Pozdzik AA, Arlt VM, et al. Probenecid prevents acute tubular necrosis in a mouse model of aristolochic acid nephropathy. Kidney Int. 2012;82(10):1105–1113. doi: 10.1038/ki.2012.264. PubMed DOI

Beckonert O, Keun HC, Ebbels TM, et al. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat Protoc. 2007;2(11):2692–2703. doi: 10.1038/nprot.2007.376. PubMed DOI

Bellomo R. Bench-to-bedside review: lactate and the kidney. Crit Care. 2002;6(4):322–326. doi: 10.1186/cc1518. PubMed DOI PMC

Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer. 2009;9(10):701–713. doi: 10.1038/nrc2693. PubMed DOI

Chatham JC, Blackband SJ. Nuclear magnetic resonance spectroscopy and imaging in animal research. ILAR J. 2001;42(3):189–208. doi: 10.1093/ilar.42.3.189. PubMed DOI

Chen Y, Chung J, Wu H, et al. Aristolochic acid suppresses DNA repair and triggers oxidative DNA damage in human kidney proximal tubular cells. Oncol Rep. 2010;24(1):141–153. doi: 10.3892/or_00000839. PubMed DOI

Chen CH, Dickman KG, Moriya M, et al. Aristolochic acid-associated urothelial cancer in Taiwan. Proc Natl Acad Sci USA. 2012;109(21):8241–8246. doi: 10.1073/pnas.1119920109. PubMed DOI PMC

Cosyns JP, Jadoul M, Squifflet JP, Wese FX, van Ypersele de Strihou C. Urothelial lesions in Chinese-herb nephropathy. Am J Kidney Dis. 1999;33(6):1011–1017. doi: 10.1016/s0272-6386(99)70136-8. PubMed DOI

Curthoys NP, Moe OW. Proximal tubule function and response to acidosis. Clin J Am Soc Nephrol. 2014;9(9):1627–1638. doi: 10.2215/CJN.10391012. PubMed DOI PMC

Debelle FD, Nortier JL, De Prez EG. Aristolochic acids induce chronic renal failure with interstitial fibrosis in salt-depleted rats. J Am Soc Nephrol. 2014;13:431–436. PubMed

Debelle FD, Nortier J, Arlt VM, et al. Effects of dexfenfluramine on aristolochic acid nephrotoxicity in a rat model for Chinese-herb nephropathy. Arch Toxicol. 2003;77(4):218–226. doi: 10.1007/s00204-003-0438-y. PubMed DOI

Dickey JS, Redon CE, Nakamura AJ, Baird BJ, Sedelnikova OA, Bonner WM. H2AX: functional roles and potential applications. Chromosoma. 2009;118(6):683–692. doi: 10.1007/s00412-009-0234-4. PubMed DOI PMC

Dickman KG, Sweet DH, Bonala R, Ray T, Wu A. Physiological and molecular characterization of aristolochic acid transport by the kidney. J Pharmacol Exp Ther. 2011;338(2):588–597. doi: 10.1124/jpet.111.180984. PubMed DOI PMC

Donehower LA. Insights into wild-type and mutant p53 functions provided by genetically engineered mice. Hum Mutat. 2014;35(6):715–727. doi: 10.1002/humu.22507. PubMed DOI

Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992;356:215–221. doi: 10.1038/356215a0. PubMed DOI

Duquesne M, Decleves AE, De Prez E, Nortier J, Colet JM. Interest of metabonomic approach in environmental nephrotoxicants: application to aristolochic acid exposure. Food Chem Toxicol. 2017;108:19–29. doi: 10.1016/j.fct.2017.07.015. PubMed DOI

Feldmeyer N, Schmeiser HH, Muehlbauer KR, et al. Further studies with a cell immortalization assay to investigate the mutation signature of aristolochic acid in human p53 sequences. Mutat Res. 2006;608(2):163–168. doi: 10.1016/j.mrgentox.2006.02.017. PubMed DOI

Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes Dev. 2012;26(12):1268–1286. doi: 10.1101/gad.190678.112. PubMed DOI PMC

Gartland KPR, Bonner FW, Nicholson JK. Investigations into the biochemical effects of region-specific nephrotoxins. Mol Pharmacol. 1988;35:242–250. PubMed

Gokmen MR, Cosyns JP, Arlt VM, et al. The epidemiology, diagnosis, and management of aristolochic acid nephropathy. Ann Intern Med. 2013;158(6):469–478. doi: 10.7326/0003-4819-158-6-201303190-00006. PubMed DOI

Grollman AP. Aristolochic acid nephropathy: harbinger of a global iatrogenic disease. Environ Mol Mutagen. 2013;54(1):1–7. doi: 10.1002/em.21756. PubMed DOI

Grollman AP, Shibutani S, Moriya M, et al. Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci USA. 2007;104(29):12129–12134. doi: 10.1073/pnas.0701248104. PubMed DOI PMC

Halouska S, Zhang B, Gaupp R, et al. Revisiting protocols for the NMR analysis of bacterial metabolomes. J Integr OMICS. 2013;3(2):120–137. doi: 10.5584/jiomics.v3i2.139. PubMed DOI PMC

Hauet T, Baumert H, Gibelin H, et al. Noninvasive monitoring of citrate, acetate, lactate, and renal medullary osmolyte excretion in urine as biomarkers of exposure to ischemic reperfusion injury. Cryobiology. 2000;41(4):280–291. doi: 10.1006/cryo.2000.2291. PubMed DOI

Heinrich M, Chan J, Wanke S, Neinhuis C, Simmonds MS. Local uses of Aristolochia species and content of nephrotoxic aristolochic acid 1 and 2—a global assessment based on bibliographic sources. J Ethnopharmacol. 2009;125(1):108–144. doi: 10.1016/j.jep.2009.05.028. PubMed DOI

Hoang ML, Chen CH, Sidorenko VS, et al. Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing. Sci Trans Med. 2013;5(197):1–20. doi: 10.1126/scitranslmed.3006200. PubMed DOI PMC

Hoang ML, Chen CH, Chen PC, et al. Aristolochic acid in the etiology of renal cell carcinoma. Cancer Epidemiol Biomark Prev. 2016;25(12):1600–1608. doi: 10.1158/1055-9965.EPI-16-0219. PubMed DOI PMC

HPA (2018) TP53, The human protein atlas. https://www.proteinatlas.org/ENSG00000141510-TP53/tissue

Hu X, Shen J, Pu X, et al. Urinary time- or dose-dependent metabolic biomarkers of aristolochic acid-induced nephrotoxicity in rats. Toxicol Sci. 2017;156(1):123–132. doi: 10.1093/toxsci/kfw244. PubMed DOI

IARC (2012) Pharmaceuticals, 100A, IARC monographs on the evaluation of carcinogenic risk to humans PubMed

Jacks T, Remington L, Williams BO, et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol. 1994;4(1):1–7. doi: 10.1016/S0960-9822(00)00002-6. PubMed DOI

Jadot I, Decleves AE, Nortier J, Caron N. An integrated view of aristolochic acid nephropathy: update of the literature. Int J Mol Sci. 2017;18(2):1–24. doi: 10.3390/ijms18020297. PubMed DOI PMC

Jelakovic B, Dika Z, Arlt VM, et al. Balkan endemic nephropathy and the causative role of aristolochic acid. Sem Nephrol. 2019;39(3):284–296. doi: 10.1016/j.semnephrol.2019.02.007. PubMed DOI

Kabanda A, Jadoul M, Lauwerys R, Bernard A, van Ypersele de Strihou C. Low molecular weight proteinuria in Chinese herbs nephropathy. Kidney Int. 1995;48(5):1571–1576. doi: 10.1038/ki.1995.449. PubMed DOI

Keun HC, Athersuch TJ. Nuclear magnetic resonance (NMR)-based metabolomics. Meth Mol Biol. 2011;708:321–334. doi: 10.1007/978-1-61737-985-7_19. PubMed DOI

Klawitter J, Haschke M, Kahle C, et al. Toxicodynamic effects of ciclosporin are reflected by metabolite profiles in the urine of healthy individuals after a single dose. Br J Clin Pharmacol. 2010;70(2):241–251. doi: 10.1111/j.1365-2125.2010.03689.x. PubMed DOI PMC

Krais AM, Muhlbauer KR, Kucab JE, et al. Comparison of the metabolic activation of environmental carcinogens in mouse embryonic stem cells and mouse embryonic fibroblasts. Toxicol In Vitro. 2015;29(1):34–43. doi: 10.1016/j.tiv.2014.09.004. PubMed DOI PMC

Krais AM, Speksnijder EN, Melis JP, et al. The impact of p53 on DNA damage and metabolic activation of the environmental carcinogen benzo[a]pyrene: effects in Trp53(+/+), Trp53(+/−) and Trp53(−/−) mice. Arch Toxicol. 2016;90(4):839–851. doi: 10.1007/s00204-015-1531-8. PubMed DOI PMC

Krais AM, Speksnijder EN, Melis JP, et al. Metabolic activation of 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine and DNA adduct formation depends on p53: studies in Trp53(+/+), Trp53(+/−) and Trp53(−/−) mice. Int J Cancer. 2016;138(4):976–982. doi: 10.1002/ijc.29836. PubMed DOI PMC

Kruiswijk F, Labuschagne CF, Vousden KH. p53 in survival, death and metabolic health: a lifeguard with a licence to kill. Nat Rev Mol Cell Biol. 2015;16(7):393–405. doi: 10.1038/nrm4007. PubMed DOI

Kucab JE, Phillips DH, Arlt VM. Metabolic activation of diesel exhaust carcinogens in primary and immortalized human TP53 knock-in (Hupki) mouse embryo fibroblasts. Environ Mol Mutagen. 2012;53(3):207–217. doi: 10.1002/em.21679. PubMed DOI

Kucab JE, van Steeg H, Luijten M, et al. TP53 mutations induced by BPDE in Xpa-WT and Xpa-Null human TP53 knock-in (Hupki) mouse embryo fibroblasts. Mutat Res. 2015;773:48–62. doi: 10.1016/j.mrfmmm.2015.01.013. PubMed DOI PMC

Kucab JE, Zou X, Morganella S, et al. A compendium of mutational signatures of environmental agents. Cell. 2019;177(4):821–836. doi: 10.1016/j.cell.2019.03.001. PubMed DOI PMC

Lane DP. p53, guardian of the genome. Nature. 1992;358:15–16. doi: 10.1038/358015a0. PubMed DOI

Lebeau C, Arlt VM, Schmeiser HH, et al. Aristolochic acid impedes endocytosis and induces DNA adducts in proximal tubule cells. Kidney Int. 2001;60(4):1332–1342. doi: 10.1046/j.1523-1755.2001.00938.x. PubMed DOI

Lebeau C, Debelle FD, Arlt VM, et al. Early proximal tubule injury in experimental aristolochic acid nephropathy: functional and histological studies. Nephrol Dial Transplant. 2005;20(11):2321–2332. doi: 10.1093/ndt/gfi042. PubMed DOI

Lemy A, Wissing KM, Rorive S, et al. Late onset of bladder urothelial carcinoma after kidney transplantation for end-stage aristolochic acid nephropathy: a case series with 15-year follow-up. Am J Kidney Dis. 2008;51(3):471–477. doi: 10.1053/j.ajkd.2007.11.015. PubMed DOI

Lenz EM, Wilson ID. Analytical strategies in metabonomics. J Proteome Res. 2007;6:443–458. doi: 10.1021/pr0605217. PubMed DOI

Levova K, Moserova M, Kotrbova V, et al. Role of cytochromes P450 1A1/2 in detoxication and activation of carcinogenic aristolochic acid I: studies with the hepatic NADPH:cytochrome P450 reductase null (HRN) mouse model. Toxicol Sci. 2011;121(1):43–56. doi: 10.1093/toxsci/kfr050. PubMed DOI

Levova K, Moserova M, Nebert DW, et al. NAD(P)H:quinone oxidoreductase expression in Cyp1a-knockout and CYP1A-humanized mouse lines and its effect on bioactivation of the carcinogen aristolochic acid I. Toxicol Appli Pharmacol. 2012;265(3):360–367. doi: 10.1016/j.taap.2012.09.004. PubMed DOI

Liu Z, Hergenhahn M, Schmeiser HH, Wogan GN, Hong A, Hollstein M. Human tumour p53 mutations are selected for in mouse embryonic fibroblasts harboring a humanized p53 gene. Proc Natl Acad Sci USA. 2004;101(9):2963–2968. doi: 10.1073/pnas.0308607101. PubMed DOI PMC

Liu X, Liu Y, Cheng M, Xiao H. Acute nephrotoxicity of aristolochic acid in vitro: metabolomics study for intracellular metabolic time-course changes. Biomarkers. 2016;21(3):233–242. doi: 10.3109/1354750X.2015.1134660. PubMed DOI

Lord GM, Hollstein M, Arlt VM, et al. DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy. Am J Kidney Dis. 2004;43(4):11–17. doi: 10.1053/j.ajkd.2003.11.024. PubMed DOI

Lou Y, Li J, Lu Y, et al. Aristolochic acid-induced destruction of organic ion transporters and fatty acid metabolic disorder in the kidney of rats. Toxicol Lett. 2011;201(1):72–79. doi: 10.1016/j.toxlet.2010.12.007. PubMed DOI

Lozano G. Mouse models of p53 functions. Cold Spring Harb Perspect Biol. 2009;2:1–12. doi: 10.1101/cshperspect.a001115. PubMed DOI PMC

Maitre L, Lau CE, Vizcaino E, et al. Assessment of metabolic phenotypic variability in children’s urine using 1H NMR spectroscopy. Sci Rep. 2017;7:1–12. doi: 10.1038/srep46082. PubMed DOI PMC

Malkin D. Li-Fraumeni syndrome. Genes Cancer. 2011;2(4):475–484. doi: 10.1177/1947601911413466. PubMed DOI PMC

Marshall DD, Powers R. Beyond the paradigm: combining mass spectrometry and nuclear magnetic resonance for metabolomics. Prog Nucl Magn Reson Spectrosc. 2017;100:1–16. doi: 10.1016/j.pnmrs.2017.01.001. PubMed DOI PMC

Mengs U, Lang W, Poch JA. The carcinogenic action of aristolochic acid in rats. Arch Toxicol. 1982;51:107–119. doi: 10.1007/BF00302751. DOI

Nedelko T, Arlt VM, Phillips DH, Hollstein M. TP53 mutation signature supports involvement of aristolochic acid in the aetiology of endemic nephropathy-associated tumours. Int J Cancer. 2009;124(4):987–990. doi: 10.1002/ijc.24006. PubMed DOI

Neild GH, Foxall PJ, Lindon JC, Holmes EC, Nicholson JK. Uroscopy in the 21st century: high-field NMR spectroscopy. Nephrol Dial Transplant. 1997;12(3):404–417. doi: 10.1093/ndt/12.3.404. PubMed DOI

Ni Y, Su M, Qiu Y, et al. Metabolic profiling using combined GC-MS and LC-MS provides a systems understanding of aristolochic acid-induced nephrotoxicity in rat. FEBS Lett. 2007;581(4):707–711. doi: 10.1016/j.febslet.2007.01.036. PubMed DOI

Nicholson JK, Connelly J, Lindon JC, Holmes E. Metabonomics: a platform for studying drug toxicity and gene function. Nat Rev. 2002;1:153–161. doi: 10.1038/nrd728. PubMed DOI

Nik-Zainal S, Kucab JE, Morganella S, et al. The genome as a record of environmental exposure. Mutagenesis. 2015;30(6):763–770. doi: 10.1093/mutage/gev073. PubMed DOI PMC

Nortier JL, Vanherweghem JL. Renal interstitial fibrosis and urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi) Toxicology. 2002;181–182:577–580. doi: 10.1016/S0300-483X(02)00486-9. PubMed DOI

Nortier JL, Muniz Martinez MC, Schmeiser HH, et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi) New Engl J Med. 2000;342(23):1686–1692. doi: 10.1056/NEJM200006083422301. PubMed DOI

Odell AF, Odell LR, Askham JM, Alogheli H, Ponnambalam S, Hollstein M. A novel p53 mutant found in iatrogenic urothelial cancers is dysfunctional and can be rescued by a second-site global suppressor mutation. J Biol Chem. 2013;288(23):16704–16714. doi: 10.1074/jbc.M112.443168. PubMed DOI PMC

Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2010;2:1–17. doi: 10.1101/cshperspect.a001008. PubMed DOI PMC

Phillips DH, Arlt VM. 32P-postlabeling analysis of DNA adducts. Methods Mol Biol. 2014;1105:127–138. doi: 10.1007/978-1-62703-739-6_10. PubMed DOI

Poon SL, Pang S, McPherson JR, et al. Genome-wide mutational signatures of aristolochic acid and its application as a screening tool. Sci Trans Med. 2013;5(197):1–10. doi: 10.1126/scitranslmed.3006086. PubMed DOI

Pozdzik AA, Salmon IJ, Debelle FD, et al. Aristolochic acid induces proximal tubule apoptosis and epithelial to mesenchymal transformation. Kidney Int. 2008;73(5):595–607. doi: 10.1038/sj.ki.5002714. PubMed DOI

Pozdzik AA, Giordano L, Li G, et al. Blocking TGF-beta signaling pathway preserves mitochondrial proteostasis and reduces early activation of PDGFRbeta + pericytes in aristolochic acid induced acute kidney injury in Wistar male rats. PLoS ONE. 2016;11(7):1–23. doi: 10.1371/journal.pone.0157288. PubMed DOI PMC

Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes. 2005;54:3427–3434. doi: 10.2337/diabetes.54.12.3427. PubMed DOI

Relman AS. Metabolic consequences of acid-base disorders. Kidney Int. 1972;1(5):347–359. doi: 10.1038/ki.1972.46. PubMed DOI

Romanov V, Whyard TC, Waltzer WC, Grollman AP, Rosenquist T. Aristolochic acid-induced apoptosis and G2 cell cycle arrest depends on ROS generation and MAP kinases activation. Arch Toxicol. 2015;89(1):47–56. doi: 10.1007/s00204-014-1249-z. PubMed DOI

Sato N, Takahashi D, Chen SM, et al. Acute nephrotoxicity of aristolochic acids in mice. J Pharm Pharmacol. 2004;56(2):221–229. doi: 10.1211/0022357023051. PubMed DOI

Schaaf GJ, De Groene EM, Maas RF, Commandeur JNM, Fink-Gremmels J. Characterization of biotransformation enzyme activities in primary rat proximal tubular cells. Chem Biol Interact. 2001;134:167–190. doi: 10.1016/S0009-2797(01)00151-X. PubMed DOI

Schmeiser HH, Bieter CA, Wiessler M, van Ypersele de Strihou C, Cosyns JP. Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy. Cancer Res. 1996;56:2025–2028. PubMed

Schmeiser HH, Stiborova M, Arlt VM. Chemical and molecular basis of the carcinogenicity of Aristolochia plants. Curr Opin Drug Discov Devel. 2009;12(1):141–148. PubMed

Schmeiser HH, Kucab JE, Arlt VM, et al. Evidence of exposure to aristolochic acid in patients with urothelial cancer from a Balkan endemic nephropathy region of Romania. Environ Mol Mutagen. 2012;53(8):636–641. doi: 10.1002/em.21732. PubMed DOI

Schmeiser HH, Stiborova M, Arlt VM. 32P-postlabeling analysis of DNA adducts. Methods Mol Biol. 2013;1044:389–401. doi: 10.1007/978-1-62703-529-3_2. PubMed DOI

Schmeiser HH, Nortier JL, Singh R, et al. Exceptionally long-term persistence of DNA adducts formed by carcinogenic aristolochic acid I in renal tissue from patients with aristolochic acid nephropathy. Int J Cancer. 2014;135(2):502–507. doi: 10.1002/ijc.28681. PubMed DOI

Scott RP, Quaggin SE. Review series: the cell biology of renal filtration. J Cell Biol. 2015;209(2):199–210. doi: 10.1083/jcb.201410017. PubMed DOI PMC

Sherr CJ, De Pinho RA. Cellular senescence as a tumor-suppressor mechanism. Cell. 2000;102:407–410. doi: 10.1016/S0092-8674(00)00046-5. PubMed DOI

Shibutani S, Dong H, Suzuki N, Ueda S, Miller F, Grollman AP. Selective toxicity of aristolochic acids I and II. Drug Metab Dispos. 2007;35(7):1217–1222. doi: 10.1124/dmd.107.014688. PubMed DOI

Simoes ML, Hockley SL, Schwerdtle T, et al. Gene expression profiles modulated by the human carcinogen aristolochic acid I in human cancer cells and their dependence on TP53 [and erratum 2018, 344, 75] Toxicol Appl Pharmacol. 2008;232(1):86–98. doi: 10.1016/j.taap.2008.06.006. PubMed DOI

Song H, Hollstein M, Xu Y. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat Cell Biol. 2007;9(5):573–580. doi: 10.1038/ncb1571. PubMed DOI

Stiborova M, Mares J, Frei E, Arlt VM, Martinek V, Schmeiser HH. The human carcinogen aristolochic acid i is activated to form DNA adducts by human NAD(P)H:quinone oxidoreductase without the contribution of acetyltransferases or sulfotransferases. Environ Mol Mutagen. 2011;52(6):448–459. doi: 10.1002/em.20642. PubMed DOI

Stiborova M, Levova K, Barta F, et al. Bioactivation versus detoxication of the urothelial carcinogen aristolochic acid I by human cytochrome P450 1A1 and 1A2. Toxicol Sci. 2012;125(2):345–358. doi: 10.1093/toxsci/kfr306. PubMed DOI PMC

Stiborova M, Martinek V, Frei E, Arlt VM, Schmeiser HH. Enzymes metabolizing aristolochic acid and their contribution to the development of aristolochic acid nephropathy and urothelial cancer. Curr Drug Metab. 2013;14:695–705. doi: 10.2174/1389200211314060006. PubMed DOI

Stiborova M, Frei E, Arlt VM, Schmeiser HH. Knockout and humanized mice as suitable tools to identify enzymes metabolizing the human carcinogen aristolochic acid. Xenobiotica. 2014;44(2):135–145. doi: 10.3109/00498254.2013.848310. PubMed DOI

Stiborova M, Levova K, Barta F, et al. The influence of dicoumarol on the bioactivation of the carcinogen aristolochic acid I in rats. Mutagenesis. 2014;29(3):189–200. doi: 10.1093/mutage/geu004. PubMed DOI

Stiborova M, Arlt VM, Schmeiser HH. Balkan endemic nephropathy: an update on its aetiology. Arch Toxicol. 2016;90(11):2595–2615. doi: 10.1007/s00204-016-1819-3. PubMed DOI PMC

Stiborova M, Arlt VM, Schmeiser HH. DNA adducts formed by aristolochic acid are unique biomarkers of exposure and explain the initiation phase of upper urothelial cancer. Int J Mol Sci. 2017;18(10):1–19. doi: 10.3390/ijms18102144. PubMed DOI PMC

Taneja P, Zhu S, Maglic D, Fry EA, Kendig RD, Inoue K. Transgenic and knockout mice models to reveal the functions of tumor suppressor genes. Clin Med Insights Oncol. 2011;5:235–257. doi: 10.4137/CMO.S7516. PubMed DOI PMC

Toncheva DI, Von Ahsen N, Atanasova SY, Dimitrov TG, Armstrong VW, Oellerich M. Identification of NQO1 and GSTs genotype frequencies in Bulgarian patients with Balkan endemic nephropathy. J Nephrol. 2004;17(3):384–389. PubMed

Turesky RJ, Yun BH, Brennan P, et al. Aristolochic acid exposure in Romania and implications for renal cell carcinoma. Br J Cancer. 2016;114(1):76–80. doi: 10.1038/bjc.2015.402. PubMed DOI PMC

Vousden KH. p53: death star. Cell. 2000;103:691–694. doi: 10.1016/S0092-8674(00)00171-9. PubMed DOI

Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol. 2007;8(4):275–283. doi: 10.1038/nrm2147. PubMed DOI

Wei Q, Xiao X, Fogle P, Dong Z. Changes in metabolic profiles during acute kidney injury and recovery following ischemia/reperfusion. PLoS One. 2014;9(9):1–13. doi: 10.1371/journal.pone.0106647. PubMed DOI PMC

Willis AJ, Indra R, Wohak LE, et al. The impact of chemotherapeutic drugs on the CYP1A1-catalysed metabolism of the environmental carcinogen benzo[a]pyrene: effects in human colorectal HCT116 TP53(+/+), TP53(+/−) and TP53(−/−) cells. Toxicology. 2018;398–399:1–12. doi: 10.1016/j.tox.2018.02.006. PubMed DOI PMC

Wohak LE, Krais AM, Kucab JE, et al. Carcinogenic polycyclic aromatic hydrocarbons induce CYP1A1 in human cells via a p53-dependent mechanism. Arch Toxicol. 2016;90(2):291–304. doi: 10.1007/s00204-014-1409-1. PubMed DOI PMC

Wohak LE, Baranski AC, Krais AM, Schmeiser HH, Phillips DH, Arlt VM. The impact of p53 function on the metabolic activation of the carcinogenic air pollutant 3-nitrobenzanthrone and its metabolites 3-aminobenzanthrone and N-hydroxy-3-aminobenzanthrone in human cells. Mutagenesis. 2018;33(4):311–321. doi: 10.1093/mutage/gey025. PubMed DOI PMC

Wohak LE, Monien B, Phillips DH, Arlt VM. Impact of p53 function on the sulfotransferase-mediated bioactivation of the alkylated polycyclic aromatic hydrocarbon 1-hydroxymethylpyrene in vitro. Environ Mol Mutagen. 2019 doi: 10.1002/em.22299. PubMed DOI

Xue X, Gong LK, Maeda K, et al. Critical role of organic anion transporters 1 and 3 in kidney accumulation and toxicity of aristolochic acid I. Mol Pharm. 2011;8(6):2183–2192. doi: 10.1021/mp100418u. PubMed DOI

Zeisel SH, Warrier M. Trimethylamine N-oxide, the microbiome, and heart and kidney disease. Ann Rev Nutr. 2017;37:157–181. doi: 10.1146/annurev-nutr-071816-064732. PubMed DOI

Zhao YY, Tang DD, Chen H, et al. Urinary metabolomics and biomarkers of aristolochic acid nephrotoxicity by UPLC-QTOF/HDMS. Bioanalysis. 2015;7(6):685–700. doi: 10.4155/bio.14.309. PubMed DOI

Zhao YY, Wang HL, Cheng XL, et al. Metabolomics analysis reveals the association between lipid abnormalities and oxidative stress, inflammation, fibrosis, and Nrf2 dysfunction in aristolochic acid-induced nephropathy. Sci Rep. 2015;5:1–13. doi: 10.1038/srep12936. PubMed DOI PMC

Zhou L, Fu P, Huang XR, Liu F, Lai KN, Lan HY. Activation of p53 promotes renal injury in acute aristolochic acid nephropathy. J Am Soc Nephrol. 2010;21(1):31–41. doi: 10.1681/ASN.2008111133. PubMed DOI PMC

Co-Exposure to Aristolochic Acids I and II Increases DNA Adduct Formation Responsible for Aristolochic Acid I-Mediated Carcinogenicity in Rats